Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients

Wyeth is now a wholly owned subsidiary of Pfizer59 enrolled

Overview

In this study we will assess as a primary objective the effect of venlafaxine retard treatment on primary care attended elderly patients with depressive syndrome. We will also study secondarily its effects on anxiety, somatic and painful symptoms of depression.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Depressive Syndrome Anxiety

Eligibility

Sex: ALLMin age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients older than 60 years * Depressive syndrome with associated anxiety symptoms, according to a symptoms intensity HAM-D17³14 Exclusion Criteria: * Participation in other studies in the last 3 months before the start of the study * Known hypersensibility to venlafaxine * Clinically significant abnormalities according to the venlafaxine labeling

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.